BITFURY-GROUP
4.11.2021 13:02:08 CET | Business Wire | Press release
Bitfury Group (“Bitfury” or the “Company”), the Bitcoin mining and crypto tech pioneer, today announced that Brian P. Brooks, former United States Acting Comptroller of the Currency, has joined the Company as Chief Executive Officer, effective October 29, 2021. Mr. Brooks will lead the 10-year-old crypto unicorn as it launches a new funding round, increases the growth of its mining business with a revolutionary new microchip design and new global data center locations, and scales a portfolio of innovative businesses that grew out of the Company’s heritage as an early Bitcoin leader. Valery Vavilov, Founder of Bitfury, will become Chairman of the Board of Directors and Chief Vision Officer, where he will continue his focus on developing over-the-horizon hardware and software innovations for Bitfury as it builds the infrastructure for a tokenized global economy.
Mr. Vavilov said, “Since our founding, Bitfury has pioneered innovative blockchain hardware and software infrastructure, and today represents a comprehensive platform addressing and enhancing the full digital asset value chain. With an eye toward the next phase in our evolution, we are thrilled to welcome Brian to the Company. Brian is a respected executive and thought leader with deep regulatory, digital asset and capital markets expertise who shares Bitfury’s vision for a decentralized peer-to peer economy. Together, we will continue to execute Bitfury’s growth strategy and help businesses, governments, organizations, and individuals leverage the blockchain to solve the most pressing challenges of today and tomorrow.”
Since its inception in 2011, Bitfury has developed into a full-service blockchain technology company and one of the world’s leading providers of large-scale digital asset infrastructure solutions. Bitfury’s platform of emerging technologies businesses includes its self-mining operations, with seven ultra-low-cost energy sites globally alongside its new United-States based Cipher Mining subsidiary; hardware products for high-performance computing needs, including seven generations of its own specialized micro-chips and next generation immersion cooling systems; and software and enterprise blockchain solutions spanning security, payments, and applications for the creator economy, among others.
Mr. Brooks said, “Bitfury is an established leader in the digital asset industry, renowned for its sustained research and development efforts and best-in-class proprietary technologies. As the adoption of – and use cases for – Bitcoin, other cryptoassets, and their underlying blockchains continues to accelerate worldwide, the Company’s diversified portfolio has immense opportunity and is well positioned for long-term success. I look forward to working alongside Valery and Bitfury’s highly experienced leadership team to grow the Company’s core businesses and scale its portfolio of new innovations.”
Brian P. Brooks Biography
Most recently, Mr. Brooks served as Chief Executive Officer of digital asset exchange and marketplace Binance.US. Previously, from May 2020 to January 2021, Mr. Brooks served as the Acting Comptroller of the Currency, where he was the administrator of the federal banking system and the chief executive of the 3,500-employee federal agency responsible for chartering and supervising banks comprising 70 percent of all banking activity in the United States. He also served as a member of the board of directors of the Federal Deposit Insurance Corporation and a voting member of the Financial Stability Oversight Council. Often referred to in the media as “the first fintech Comptroller” and “CryptoComptroller” for his work advancing financial innovation, Mr. Brooks led the government’s efforts to provide regulatory clarity for stablecoins, digital asset custody, and the development of blockchain payment networks, and granted the first federal bank charter to a cryptocurrency company. He also launched Project REACh, a national partnership of civil rights organizations, tech companies, and banks to promote financial inclusion through greater access to credit and capital.
From 2018 to 2020, Mr. Brooks served as Chief Legal Officer of Coinbase Global, Inc., where he led legal, compliance, internal audit, government relations, and global investigations groups at the digital asset platform. From 2014 to 2018, he served as Executive Vice President, General Counsel, and Corporate Secretary of Fannie Mae, a $3.2 trillion asset public company that is the world’s largest investor in single-family and multifamily mortgage assets, and from 2011 to 2014, as Vice Chairman of OneWest Bank, N.A. Before joining OneWest Bank, N.A., he served as managing partner of O’Melveny & Myers LLP’s Washington, D.C. office.
Mr. Brooks also serves as an adviser or board member for a number of financial and fintech companies. Mr. Brooks received his BA from Harvard University and his JD from the University of Chicago.
About Bitfury Group
Bitfury Group is the world's leading technology company unlocking the full value chain of Bitcoin and other digital assets. Bitfury™ has built on its heritage as one of the earliest Bitcoin miners and developers of mining equipment to create solutions for the future – solutions such as the Crystal™ Blockchain advanced analytics platform, which helps law enforcement and private sector clients make cryptoassets safer and more compliant; the Liquidstack immersion cooling business, which dramatically reduces data center energy usage and makes Bitcoin mining and high performance computing more environmentally sustainable; Axelera AI, which unlocks the potential of artificial intelligence with the world’s most advanced AI technologies; Surround, providing blockchain-based solutions for the creator economy including digital rights management, payments, and NFT support; and others. Our mission is to make the world more secure and trusted by innovating at every level of technology – hardware, security, and software – to put trust back into the equation. To learn more, visit www.bitfury.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005386/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
